Northway Biotech
16.5.2023 14:32:41 CEST | ACCESS Newswire | Press release
KIEL, GERMANY / ACCESSWIRE / May 16, 2023 / tiakis Biotech AG (tiakis), in collaboration with its CDMO partner Northway Biotech, is pleased to announce the successful completion of a technology transfer and ramp-up of manufacturing capabilities for Tiprelestat, a pioneering anti-inflammatory and tissue-protective drug being developed for the prevention of postoperative inflammatory complications following major surgery, treatment of COVID-19 and pulmonary arterial hypertension. For the first time worldwide, a clinical trial is being supported by Tiprelestat study material produced at an industrial fermentation scale, representing a ten-fold increase in manufacturing potential to 3,000 L.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.tiakis Biotech AG and Northway Biotech: Successful Tech Transfer and Expansion of Manufacturing Capabilities for Tiprelestat
"The marked increase in manufacturing capabilities lays the foundation for the next stage of tiakis' development programs, with the recent start of our COMCOVID phase Ib/II clinical trial being a prime example," said Martin Voss, tiakis Biotech AG co-CEO.
The enhanced production capabilities is a result of the successful completion of a technology transfer and subsequent ramp-up program, achieved in a short time through close collaboration with end-to-end biologics CDMO Northway Biotech, based in Vilnius, Lithuania.
Reflecting on this milestone, Vladas Algirdas Bumelis, CEO of Northway Biotech, stated: "The confidence our partners have placed in our two-decade-long expertise has enabled us to collaboratively scale up the process and meet tiakis' deadlines. Our state-of-the-art 3,000 L stainless-steel fermenter train was utilized to carry out the implementation successfully. We extend our sincere well-wishes to our partners as they move forward with their innovative drug through clinical trials, and we look forward to future collaborations."
André Markmann, VP Business Development of Northway Biotech, added: "This partnership exemplifies our commitment to assist our partners in achieving their objectives by leveraging our technical expertise and operational capabilities. We are immensely proud to be part of this groundbreaking project, which addresses a significant unmet medical need."
By attaining this pharmaceutical and technological milestone, tiakis and Northway Biotech have demonstrated their capabilities to pave the way towards groundbreaking achievements as pioneers in their respective fields. The success of this fast-paced project is characterized by strong collaborative interaction, mutual trust, and flexibility between the two companies.
About Tiprelestat
tiakis biopharmaceutical drug candidate Tiprelestat promises an excellent therapeutic benefit-risk profile for use as an anti-inflammatory and tissue-protective drug. Tiprelestat is identical to the human protein elafin with high specificity for tissue-destroying and inflammation-promoting proteases. The development program of Tiprelestat is focused on the late-stage development of Tiprelestat in major surgery and early-stage development in pulmonary arterial hypertension (PAH) and COVID-19.
About tiakis Biotech AG
tiakis focuses on the discovery and development of therapeutic solutions based on its innovative biopharmaceutical Tiprelestat for life-threatening surgeries and life-threatening diseases such as PAH and COVID-19. tiakis seeks partners and investors for the development, commercial-scale manufacturing, marketing and distribution of the product. The company tiakis Biotech AG is located in Kiel, Germany (www.tiakis.bio).
About Northway Biotech
Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced, professional team executes projects at any stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company's wide-ranging expertise and vertically integrated service offering translate to the ability to rapidly execute multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development and commercial manufacturing. Northway Biotech is a privately owned company founded in 2004 and located in Vilnius, Lithuania, London, United Kingdom, and in Waltham, MA, US. Further information can be found on Northway's website www.northwaybiotech.com.
Contact Information
Vladas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com
SOURCE: Northway Biotech
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/755218/tiakis-Biotech-AG-and-Northway-Biotech-Successful-Tech-Transfer-and-Expansion-of-Manufacturing-Capabilities-for-Tiprelestat
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Chervon Appoints Stephen Sarnocinski to President - End User Research, Sales and Service - OPE Commercial Landscaping Market Global21.10.2026 16:00:00 CEST | Press release
NAPERVILLE, IL / ACCESS Newswire / October 21, 2026 / Stephen (Sarno) Sarnocinski is named President - End User Research, Sales and Service - OPE Commercial Landscaping Market Global, effective October 20, 2026, reporting to Joe Galli, CEO. Sarnocinski brings 21+ years of extraordinary experience, performance and leadership to Chervon. He is a high-potential senior executive with an exciting future ahead at Chervon. Sarno will now assume a new role at Chervon focused on pioneering and developing the OPE Commercial Landscaper User Vertical. Sarno was most recently a Senior Vice President - Job Site Solutions for TTI/Milwaukee, leading the Utility, Energy, Communications and Mining Verticals. Over the past 10 years he has held increasingly responsible JSS positions in the Eastern USA. Before his JSS role, he was responsible for Milwaukee East Coast Service Operations. He started his TTI/Milwaukee career rising through a series of store coverage and territory management positions. Before
DataTracks Launches Nova, Filing Software that Takes UK Micro-Entities Through HMRC and Companies House on One Set of Figures21.10.2026 15:45:00 CEST | Press release
LONDON, UK / ACCESS Newswire / October 21, 2026 / DataTracks, the regulatory reporting software and services provider, has launched DataTracks Nova, software that prepares a UK micro-entity's accounts and Corporation Tax return from a single set of figures, produces the iXBRL that HMRC requires now and Companies House will require from 1 April 2028, and files the CT600 with HMRC. Companies House accounts filing runs from the same data in the same product. Until 31 March 2026, many smaller UK companies with straightforward affairs had a free way to do this themselves. CATO (Company Accounts and Tax Online) was a free HMRC online service, run jointly with Companies House, that let a company prepare and submit its own Corporation Tax return and accounts through a simple web form, with no software to buy and no accountant needed. It was only open to companies filing without an agent. HMRC closed it on 31 March 2026. Since 1 April 2026, companies have generally had to use commercial softwar
Fermi Provides Letter to Shareholders from CEO Lee McIntire on Financing Fermi's Next Chapter21.10.2026 14:30:00 CEST | Press release
DALLAS, TX / ACCESS Newswire / October 21, 2026 / Fermi Inc. (NASDAQ:FRMI)(LSE:FRMI), operating as Fermi America™ ("Fermi" or the "Company") today provided the following letter to shareholders from CEO Lee McIntire: Dear Fellow Shareholders, We are living through an extraordinary moment in the development of American infrastructure. As artificial intelligence reshapes industries and economies, reliable power has become one of the most strategically important and sought-after assets in the world. Fermi was founded with this opportunity in mind. At Fermi's Project Matador, we are pursuing one of the most ambitious power and infrastructure developments in the country, designed to deliver the scale and reliability required by the next generation of computing. Throughout my decades in global infrastructure and construction, I have learned that creating a successful infrastructure business requires more than assembling valuable assets. It requires judgment and financial discipline to turn th
PFN and Tenstorrent Selected for NEDO Project on "xPU Design and Development Incorporating Photonics Electronics Integration Technology"21.10.2026 14:00:00 CEST | Press release
TOKYO, JP / ACCESS Newswire / October 21, 2026 / Preferred Networks, Inc. (PFN) and Tenstorrent USA, Inc. (Tenstorrent) have announced today that their joint proposal has been selected by Japan's New Energy and Industrial Technology Development Organization (NEDO) for the theme "xPU Design and Development Incorporating Photonics-Electronics Integration Technology" (*1) under the NEDO-sponsored "Research and Development Project of the Enhanced Infrastructures for Post-5G Information and Communication Systems / Development of manufacturing technologies for advanced semiconductors." AI models and workloads continue to increase in size and computational complexity, and are being adopted across a wide range of industries. This rapid growth has further increased the compute needed for model training and inference, driving demand for more scalable and efficient AI infrastructure. Through a joint research and development project, PFN and Tenstorrent aim to develop a system-level integration of
Polaris Renewable Energy Awards Key Supply Contract and Issues Notice to Proceed on Punta Lima Battery Storage Investment20.10.2026 23:10:00 CEST | Press release
TORONTO, ON / ACCESS Newswire / October 20, 2026 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris" or the "Company") is pleased to announce that it has awarded and executed a contract with Trina Energy Storage Solutions (Singapore) Pte. Ltd. ("Trina Storage") for the supply of battery energy storage systems ("BESS") for the Company's Punta Lima project in Puerto Rico. Trina Storage is a global utility-scale energy storage provider with 30 GWh of BESS projects commissioned and under execution worldwide, including more than 6 GWh across Latin America and the Caribbean. The Punta Lima BESS project is being advanced under Puerto Rico's Accelerated Storage Addition Program ("ASAP"), a strategic initiative designed to strengthen grid reliability through the deployment of utility-scale battery energy storage systems co-located with existing generation facilities. As background, on June 5, 2026, Polaris Power US, Inc. ("PPUS") fully executed the BESS Standard Offer Agreement (the "SO1 Agree
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom